Fiona McPhee Selected Research

Fiona McPhee Research Topics

Disease

50	Infections 05/2021 - 01/2012
28	Chronic Hepatitis C 01/2019 - 01/2012
18	Fibrosis (Cirrhosis) 01/2019 - 09/2012
5	Headache (Headaches) 06/2014 - 03/2012
4	Hepatitis C 01/2016 - 01/2012
4	Diarrhea 06/2014 - 03/2012
2	Viremia 05/2021 - 01/2021
2	Liver Diseases (Liver Disease) 10/2019 - 05/2016
2	Anemia 03/2016 - 01/2016
2	Exanthema (Rash) 03/2016 - 01/2016
2	Fever (Fevers) 06/2014 - 01/2014
2	Nasopharyngitis 06/2014 - 04/2013
2	Virus Diseases (Viral Diseases) 04/2013 - 01/2013
1	Coinfection 05/2021
1	Reinfection 01/2021
1	Hepatitis E 10/2020
1	Hepatocellular Carcinoma (Hepatoma) 09/2018
1	Chronic Hepatitis B 09/2018
1	Respiratory Tract Infections (Respiratory Tract Infection) 03/2018
1	Jaundice (Icterus) 03/2018
1	Nausea 03/2018
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2015
1	Alopecia (Baldness) 01/2014
1	Hyperbilirubinemia 04/2013

Drug/Important Bio-Agent (IBA)

42	daclatasvirIBA 01/2019 - 03/2012
32	Ribavirin (Virazole)FDA LinkGeneric 01/2019 - 01/2012
26	asunaprevirIBA 09/2018 - 03/2012
14	InterferonsIBA 09/2018 - 03/2012
13	RNA (Ribonucleic Acid)IBA 05/2021 - 01/2012
13	Antiviral Agents (Antivirals)IBA 05/2021 - 01/2012
13	Protease Inhibitors (Protease Inhibitor)IBA 12/2020 - 04/2012
9	8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamideIBA 09/2018 - 02/2014
8	SofosbuvirIBA 01/2019 - 01/2014
4	telaprevirIBA 03/2016 - 01/2014
4	peginterferon alfa-2a (Pegasys)FDA Link 01/2016 - 09/2012
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 09/2018 - 06/2014
3	Transaminases (Aminotransferases)IBA 03/2018 - 03/2012
2	DNA (Deoxyribonucleic Acid)IBA 05/2021 - 09/2018
2	Alanine Transaminase (SGPT)IBA 03/2018 - 06/2014
2	Proteins (Proteins, Gene)FDA Link 05/2016 - 05/2015
2	SimeprevirIBA 02/2016 - 01/2016
2	peginterferon lambda-1aIBA 01/2016 - 09/2013
2	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 02/2014 - 01/2014
1	Immunoglobulin M (IgM)IBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	Viral RNAIBA 10/2020
1	entecavir FDA Link 09/2018
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 09/2018
1	Amino Acids FDA Link 12/2016
1	TabletsIBA 11/2016
1	Interferon-alpha (Interferon Alfa)IBA 11/2016
1	NucleotidesIBA 05/2016
1	Hemoglobins (Hemoglobin)IBA 03/2016
1	sofosbuvir drug combination ledipasvirIBA 01/2016
1	Pharmaceutical PreparationsIBA 01/2016
1	N 30IBA 06/2015
1	Interferon LambdaIBA 01/2015
1	Phosphotransferases (Kinase)IBA 01/2015
1	p21-Activated KinasesIBA 01/2015
1	Complement System Proteins (Complement)IBA 01/2015
1	Complementary DNA (cDNA)IBA 01/2015
1	GlucocorticoidsIBA 01/2015
1	Small Interfering RNA (siRNA)IBA 01/2015
1	EnzymesIBA 03/2014
1	BMS-605339IBA 03/2014
1	NucleosidesIBA 02/2014
1	InterleukinsIBA 02/2014
1	peginterferon alfa-2b (Pegintron)FDA Link 01/2014
1	Peptide Hydrolases (Proteases)FDA Link 04/2013
1	Monoclonal AntibodiesIBA 01/2013
1	LigandsIBA 01/2013
1	NivolumabIBA 01/2013

Therapy/Procedure

17	Therapeutics 10/2019 - 01/2012
1	Liver Transplantation 05/2016
1	Aftercare (After-Treatment) 01/2016
1	Retreatment 01/2016
1	Duration of Therapy 02/2015